Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial-Reference-Cited by-同舟云学术

Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial

Published:2021-08 Issue: Volume:337 Page:21-27
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Ulander Lotta,Tolppanen Heli,Hartman Otto,Rissanen Tuomas T.,Paakkanen Riitta,Kuusisto Jouni,Anttonen Olli,Nieminen Tuomo,Yrjölä Jaana,Ryysy Ransu,Drews Teemu,Utriainen Seppo,Karjalainen Pasi,Anttila Ismo,Nurmi Katariina,Silventoinen Kristiina,Koskinen Miika,Kovanen Petri T.,Lehtonen Jukka,Eklund Kari K.,Sinisalo Juha

Funder

Jenny and Antti Wihuri Foundation

Paavo Nurmi Foundation

Finnish Cultural Foundation

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference21 articles.

1. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines;Kuznik;J. Immunol.,2011

2. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes;Jang;Rheumatology (Oxford),2006

3. Antiinflammatory therapy with canakinumab for atherosclerotic disease;Ridker;N. Engl. J. Med.,2017